ArticleMedicine2026
Linear relationship between the Framingham Steatosis Index (FSI) and colorectal cancer (1999-2018): A nationwide cross-sectional study based on NHANES.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) poses a significant challenge to public health worldwide. Mounting evidence implicates fatty liver disease as an accelerator of CRC. This study investigated the association between the Framingham Steatosis Index (FSI), also known as the Fatty Liver Substitution Index, and CRC susceptibility. This study aims to provide a theoretical foundation for developing preventive strategies and therapeutic interventions for individuals at high risk of CRC, thereby ultimately improving treatment outcomes. This study employed 1,01,316 baseline records from the NHANES database (1999-2018). The application of stringent eligibility criteria yielded 42,732 qualified subjects: 274 individuals with CRC and 42,458 control individuals. FSI quantification was performed using standardized procedures. Following covariate adjustment, analyses were performed using multivariate logistic regression, restricted cubic spline models, and stratification approaches to ascertain the relationship between FSI scores and CRC susceptibility. Within crude models, increased FSI levels were positively associated with CRC susceptibility, maintaining this direct association after covariate adjustment. Subgroup evaluations generated uniformly consistent findings across population categories, confirming the robustness of the findings. Dose-response analyses revealed a significant linear correlation, in which an increase in FSI magnitude corresponded to a heightened CRC probability. Increasing FSI levels increase the risk of developing CRC, providing new theoretical support for the diagnosis and treatment of CRC. However, cross-sectional studies aim to establish associations, and the causal relationship between the 2 requires further research to validate and assess the feasibility of applying these findings in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.